Potential utility of precision medicine for older adults with polypharmacy: a case series study

References

• RohrerJEGarrisonGOberhelmanSAMeunierMREpidemiology of polypharmacy among family medicine patients at hospital dischargeJ Prim Care Community Health20134210110523799716
   PubMedGoogle Scholar
• QatoDMAlexanderGCContiRMUse of prescription and over-the-counter medications and dietary supplements among older adults in the United StatesJAMA2008300242867287819109115
   PubMed Web of Science ®Google Scholar
• MaherRLHanlonJHajjarERClinical consequences of polypharmacy in elderlyExpert Opin Drug Saf2014131576524073682
   PubMed Web of Science ®Google Scholar
• SehgalVBajwaSJSehgalRBajajAKhairaUKresseVPolypharmacy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospitalJ Family Med Prim Care20132219419924479078
   PubMedGoogle Scholar
• DavidSPJohnsonSGBergerACMaking personalized health care even more personalized: insights from activities of the IOM genomics roundtableAnn Fam Med201513437338026195686
   PubMed Web of Science ®Google Scholar
• VivotABoutronIRavaudPPorcherRGuidance for pharmacogenomic biomarker testing in labels of FDA-approved drugsGenet Med201517973373825521333
   PubMed Web of Science ®Google Scholar
• CavallariLHJeongHBressARole of cytochrome P450 genotype in the steps toward personalized drug therapyPharmgenomics Pers Med2011412313623226058
   PubMedGoogle Scholar
• BielinskiSJOlsonJEPathakJPreemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocolMayo Clin Proc2014891253324388019
   PubMed Web of Science ®Google Scholar
• KaufmanALSpitzJJacobsMEvidence for clinical implementation of pharmacogenomics in cardiac drugsMayo Clin Proc201590671672926046407
   PubMed Web of Science ®Google Scholar
• JohnsonMRichardCBogdanRKiddRWarfarin dosing in a patient with CYP2C9(*)3(*)3 and VKORC1-1639 AA genotypesCase Rep Genet2014201441374324627811
   PubMedGoogle Scholar
• LiJBluthMHPharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapyPharmgenomics Pers Med20114113323226051
   PubMedGoogle Scholar
• DeekenJFFiggWDBatesSESparreboomAToward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogeneticsAnticancer Drugs200718211112617159598
   PubMed Web of Science ®Google Scholar
• WijnenPAOp den BuijschRADrentMReview article: the prevalence and clinical relevance of cytochrome P450 polymorphismsAliment Pharmacol Ther200726Suppl 221121918081664
   PubMed Web of Science ®Google Scholar
• OetjensMTDennyJCRitchieMDAssessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical recordsPharmacogenomics201314773574423651022
   PubMed Web of Science ®Google Scholar
• HiratsukaMSasakiTMizugakiMGenetic testing for pharmacogenetics and its clinical application in drug therapyClin Chim Acta20063631–217718616126184
   PubMed Web of Science ®Google Scholar
• ThornCFKleinTEAltmanRBPharmGKB: the pharmacogenomics knowledge baseMethods Mol Biol2013101531132023824865
   PubMedGoogle Scholar
• FinkelsteinJChaEScharfSMChronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidityInt J Chron Obstruct Pulmon Dis2009433734919802349
   PubMedGoogle Scholar
• ChaudhrySIMcAvayGChenSRisk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health StudyJ Am Coll Cardiol201361663564223391194
   PubMed Web of Science ®Google Scholar
• SimSCIngelman-SundbergMPharmacogenomic biomarkers: new tools in current and future drug therapyTrends Pharmacol Sci2011322728121185092
   PubMed Web of Science ®Google Scholar
• LeeSJGoldsteinJAFunctionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping testsPharmacogenomics20056435737116004554
   PubMed Web of Science ®Google Scholar
• LambaJKLinYSSchuetzEGThummelKEGenetic contribution to variable human CYP3A-mediated metabolismAdv Drug Deliv Rev200254101271129412406645
   PubMed Web of Science ®Google Scholar
• FlockhartDAO’KaneDWilliamsMSPharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. American College of Medical Genetics Policy StatementGenet Med200810213915018281922
   PubMed Web of Science ®Google Scholar
• MeckleyLMWittkowskyAKRiederMJRettieAEVeenstraDLAn analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patientsThromb Haemost2008100222923918690342
   PubMed Web of Science ®Google Scholar
• ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: Part IClin Pharmacokinet2009481168972319817501
   PubMed Web of Science ®Google Scholar
• LymperopoulosAMcCrinkKABrillAImpact of CYP2D6 genetic variation on the response of the cardiovascular patient to carvedilol and metoprololCurr Drug Metab2015171303626537419
   PubMed Web of Science ®Google Scholar
• BlakeCMKharaschEDSchwabMNagelePA meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokineticsClin Pharmacol Ther201394339439923665868
   PubMed Web of Science ®Google Scholar
• HocumBTWhiteJRJrHeckJW3Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testingAm J Health Syst Pharm2016732616726721535
   PubMed Web of Science ®Google Scholar
• ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: part IIClin Pharmacokinet2009481276180419902987
   PubMed Web of Science ®Google Scholar
• VerbeurgtPMamiyaTOesterheldJHow common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotypingPharmacogenomics201415565566524798722
   PubMed Web of Science ®Google Scholar
• BaudhuinLMMillerWLTrainLRelation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failureAm J Cardiol2010106340240820643254
   PubMed Web of Science ®Google Scholar
• BaeJWJangCGLeeSYEffects of CYP2D6 genetic polymorphism on the pharmacokinetics of carvedilolFASEB J200721lb363
   Google Scholar
• ShihmanterRNulmanIGolandSVariation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failureJ Clin Pharm Ther201439443243824673480
   PubMed Web of Science ®Google Scholar
• RellingMVKleinTECPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClin Pharmacol Ther201189346446721270786
   PubMed Web of Science ®Google Scholar
• SwenJJNijenhuisMde BoerAPharmacogenetics: from bench to byte – an update of guidelinesClin Pharmacol Ther201189566267321412232
   PubMed Web of Science ®Google Scholar
• CareyTSBodenSDA critical guide to case series reportsSpine200328151631163412897483
   PubMed Web of Science ®Google Scholar
• BrixnerDBiltajiEBressAThe effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacyJ Med Econ201619321322826478982
   PubMed Web of Science ®Google Scholar
• Isidoro-GarcíaMSánchez-MartínAGarcía-BerrocalBRomán-CurtoCPrimun non nocere, polypharmacy and pharmacogeneticsPharmacogenomics201516171903190526554320
   PubMed Web of Science ®Google Scholar
• NightingaleGHajjarESwartzKAndrel-SendeckiJChapmanAEvaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancerJ Clin Oncol201533131453145925800766
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society 2012 Beers Criteria Update Expert PanelAmerican Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adultsJ Am Geriatr Soc201260461663122376048
   PubMed Web of Science ®Google Scholar
• GallagherPRyanCByrneSKennedyJO’MahonyDSTOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validationInt J Clin Pharmacol Ther2008462728318218287
   PubMed Web of Science ®Google Scholar
• SaldivarJSTaylorDSugarmanEAInitial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facilityPharmgenomics Pers Med201691626855597
   PubMed Web of Science ®Google Scholar
• ShahRRGaedigkALLerenaAEichelbaumMStinglJSmithRLCYP450 genotype and pharmacogenetic association studies: a critical appraisalPharmacogenomics201617325927526780308
   PubMed Web of Science ®Google Scholar
• LeeJSCheongHSKimLHScreening of genetic polymorphisms of CYP3A4 and CYP3A5 genesKorean J Physiol Pharmacol201317647948424381495
   PubMed Web of Science ®Google Scholar
• Johansen TaberKADickinsonBDPharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialtiesPharmgenomics Pers Med2014714516225045280
   PubMedGoogle Scholar
• HagaSBBurkeWGinsburgGSMillsRAgansRPrimary care physicians’ knowledge of and experience with pharmacogenetic testingClin Genet201282438839422698141
   PubMed Web of Science ®Google Scholar
• ObaraTAbeSSatohMGutiérrez UbedaSRYoshimachiSGotoTAwareness regarding clinical application of pharmacogenetics among Japanese pharmacistsPharmgenomics Pers Med20158354125691815
   PubMed Web of Science ®Google Scholar
• Abul-HusnNSOwusu ObengASandersonSCGottesmanOScottSAImplementation and utilization of genetic testing in personalized medicinePharmgenomics Pers Med2014722724025206309
   PubMedGoogle Scholar
• Mikat-StevensNALarsonIATariniBAPrimary-care providers’ perceived barriers to integration of genetics services: a systematic review of the literatureGenet Med201517316917625210938
   PubMed Web of Science ®Google Scholar
• OverbyCLErwinALAbul-HusnNSPhysician attitudes toward adopting genome-guided prescribing through clinical decision supportJ Pers Med201441354925562141
   PubMedGoogle Scholar
• MillsRVooraDPeyserBHagaSBDelivering pharmacogenetic testing in a primary care settingPharmgenomics Pers Med2013610511224101877
   PubMedGoogle Scholar
• CarlsonBVanderbilt pioneers bedside geneticsBiotechnol Healthc2012923132
   Google Scholar
• O’DonnellPHDanaheyKJacobsMAdoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project”Am J Med Genet C Semin Med Genet2014166C1687524616296
   PubMed Web of Science ®Google Scholar
• ThirumaranRKHeckJWHocumBTCYP450 genotyping and cumulative drug-gene interactions: an update for precision medicinePers Med201613158
   Web of Science ®Google Scholar